Research Analysts Offer Predictions for Genelux Q2 Earnings

Genelux Co. (NASDAQ:GNLX) – Equities research analysts at HC Wainwright increased their Q2 2025 EPS estimates for shares of Genelux in a report issued on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.22) per share for the quarter, up from their prior forecast of ($0.24). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q3 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.96) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($0.68) EPS, FY2028 earnings at $0.44 EPS and FY2029 earnings at $1.44 EPS.

Separately, Benchmark lowered their target price on Genelux from $25.00 to $23.00 and set a “speculative buy” rating on the stock in a research report on Thursday. Four equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $17.75.

Genelux Price Performance

Shares of GNLX stock opened at $2.96 on Friday. The stock has a market capitalization of $111.70 million, a PE ratio of -3.12 and a beta of -0.33. The business has a 50-day moving average of $2.96 and a 200 day moving average of $3.11. Genelux has a 1-year low of $1.60 and a 1-year high of $5.89.

Genelux (NASDAQ:GNLX) last released its earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03.

Institutional Investors Weigh In On Genelux

A number of institutional investors have recently added to or reduced their stakes in GNLX. Virtu Financial LLC bought a new position in shares of Genelux during the fourth quarter worth $25,000. Advisor Resource Council purchased a new stake in Genelux in the 1st quarter worth $34,000. Liberty Wealth Management LLC purchased a new position in shares of Genelux during the first quarter valued at about $45,000. Apollon Wealth Management LLC grew its position in shares of Genelux by 20.4% during the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company’s stock valued at $40,000 after purchasing an additional 2,857 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Genelux in the fourth quarter worth about $41,000. 37.33% of the stock is owned by hedge funds and other institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.